Brief: USPTO Grants Acurx Pharmaceuticals New Patent For Ibezapolstat To Treat CDI
17/07/2024 12:19
July 17 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* USPTO GRANTS ACURX PHARMACEUTICALS NEW PATENT FOR
IBEZAPOLSTAT
TO TREAT CDI WHILE REDUCING RECURRENCE OF INFECTION AND
IMPROVING HEALTH OF THE GUT MICROBIOME
Source text for Eikon: ID:nPn3nkN8Ca
Further company coverage: ACXP.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln